Acrivon Therapeutics (NASDAQ:ACRV) Stock Lifted to Hold by Wall Street Zen

Acrivon Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen upgraded Acrivon Therapeutics from “sell” to “hold.” Overall, MarketBeat reports a “Moderate Buy” consensus rating and a $13.50 target price, with four Buy ratings and one Sell rating.
  • Acrivon opened at $1.15, near its 12-month low of $0.97 and well below its $3.56 high; its market capitalization was about $49.3 million.
  • The company reported quarterly EPS of ($0.42), beating analyst estimates of ($0.44) by $0.02. Acrivon is a clinical-stage cancer drug developer studying candidate ACR-368.
  • Five stocks to consider instead of Acrivon Therapeutics.

Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday, Wall Street Zen reports.

Other equities research analysts have also issued reports about the stock. Citizens Jmp reiterated a "market outperform" rating on shares of Acrivon Therapeutics in a research note on Tuesday. Jefferies Financial Group restated a "buy" rating on shares of Acrivon Therapeutics in a research note on Wednesday, November 11th. Finally, Weiss Ratings upgraded Acrivon Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Friday, October 9th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Acrivon Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $13.50.

View Our Latest Report on ACRV

Acrivon Therapeutics Price Performance

NASDAQ:ACRV opened at $1.15 on Friday. Acrivon Therapeutics has a 12 month low of $0.97 and a 12 month high of $3.56. The firm has a market capitalization of $49.28 million, a PE ratio of -0.63 and a beta of 1.96. The business's fifty day moving average price is $1.76 and its 200 day moving average price is $1.74.

Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) last announced its quarterly earnings results on Monday, November 16th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.02. As a group, equities analysts anticipate that Acrivon Therapeutics will post -1.69 EPS for the current year.

Insider Buying and Selling at Acrivon Therapeutics

In related news, CEO Peter Blume-Jensen sold 14,036 shares of the firm's stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $2.21, for a total transaction of $31,019.56. Following the transaction, the chief executive officer owned 2,230,052 shares of the company's stock, valued at $4,928,414.92. This trade represents a 0.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 17,444 shares of company stock worth $36,320 in the last three months. 10.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Acrivon Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace LLP increased its holdings in shares of Acrivon Therapeutics by 2.0% in the third quarter. Marshall Wace LLP now owns 542,344 shares of the company's stock valued at $1,112,000 after purchasing an additional 10,488 shares during the period. Empowered Funds LLC purchased a new position in Acrivon Therapeutics during the 3rd quarter worth $117,000. StoneX Group Inc. purchased a new position in Acrivon Therapeutics during the 3rd quarter worth $43,000. Spark Investment Management LLC acquired a new stake in shares of Acrivon Therapeutics in the 2nd quarter worth $50,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Acrivon Therapeutics by 19.6% in the 1st quarter. Renaissance Technologies LLC now owns 758,440 shares of the company's stock worth $1,054,000 after acquiring an additional 124,271 shares during the period. 71.62% of the stock is owned by institutional investors and hedge funds.

Acrivon Therapeutics Company Profile

(Get Free Report)

Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for cancer. Its research focuses on identifying treatments for patients whose tumors have molecular characteristics that may make them more likely to respond to a particular therapy. The company's Acrivon Predictive Precision Proteomics (AP3) platform analyzes protein activity in tumor samples to identify these characteristics and help guide patient selection. Acrivon's clinical-stage candidate ACR-368 is a small-molecule inhibitor of the CHK1 and CHK2 enzymes being studied in solid tumors.

See Also

Analyst Recommendations for Acrivon Therapeutics (NASDAQ:ACRV)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Acrivon Therapeutics Right Now?

Before you consider Acrivon Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acrivon Therapeutics wasn't on the list.

While Acrivon Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines